S.J.L.B. received support from the Netherlands Heart Foundation, Dutch Diabetes Research Foundation, and Dutch Kidney Foundation, together participating in the framework of the Center for Translational Molecular Medicine (project PREDICCt (Grant 01C-104-07).
J.S. was previously employed by B.R.A.H.M.S, a company that manufactures and holds patent rights on the NT-proSST assay.
PRvD, GWDL, LvE, KHG, HJGB, NK reported that they have no potential conflicts of interest relevant to this article.
PRvD is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. PRvD: Statistical analysis, writing manuscript. GWDL: Statistical analysis, writing and critically reviewing manuscript. LvE: Critically reviewing manuscript. JS: Analysis of samples, critically reviewing manuscript. KG: Statistical analysis, critically reviewing manuscript. HJGB: Design, critically reviewing manuscript. SJLB: Design, critically reviewing manuscript. NK: Design, critically reviewing manuscript. All authors read and approved the final manuscript.
Joachim Struck, Currently: Sphingotec GmbH, Hennigsdorf, Germany. At the time of analysis: Thermo Fisher, Hennigsdorf, Germany.
The hormone somatostatin inhibits growth hormone release from the pituitary gland and is theoretically linked to diabetes and diabetes related complications. This study aimed to investigate the relationship between levels of the stable somatostatin precursor, N-terminal prosomatostatin (NT-proSST), with mortality in type 2 diabetes (T2DM) patients.
In 1,326 T2DM outpatients, participating in this ZODIAC prospective cohort study, Cox proportional hazards models were used to investigate the independent relationship between plasma NT-proSST concentrations with all-cause and cardiovascular mortality.
Median concentration of NT-proSST was 592 [IQR 450–783] pmol/L. During follow-up for 6 [3–10] years, 413 (31%) patients died, of which 176 deaths (43%) were attributable to cardiovascular causes. The age and sex adjusted hazard ratios (HRs) for all-cause and cardiovascular mortality were 1.48 (95%CI 1.14 - 1.93) and 2.21 (95%CI 1.49 - 3.28). However, after further adjustment for cardiovascular risk factors there was no independent association of log NT-proSST with mortality, which was almost entirely attributable to adjustment for serum creatinine. There were no significant differences in Harrell’s C statistics to predict mortality for the models with and without NT-proSST: both 0.79 (95%CI 0.77 – 0.82) and 0.81 (95%CI 0.77 – 0.84).
NT-proSST is unsuitable as a biomarker for cardiovascular and all-cause mortality in stable outpatients with T2DM.
Yamada T, Soll AH, Park J, Elashoff J. Autonomic regulation of somatostatin release: studies with primary cultures of canine fundic mucosal cells. Am J Physiol. 1984;247(5 Pt 1):G567–73. PubMed
Bersani M, Thim L, Baldissera FG, Holst JJ. Prosomatostatin 1–64 is a major product of somatostatin gene expression in pancreas and gut. J Biol Chem. 1989;264:10633–6. PubMed
Slagman A, Searle J, von Recum J, Holert F, Ziera T, Struck J, et al. Prosomatostatin as a marker for acute heart failure in unselected patients in the emergency department. Clin Chem. 2013;59:B-238.
Ubink-Veltmaat LJ, Bilo HJG, Groenier KH, Rischen RO, Meyboom-de Jong B. Shared care with task delegation to nurses for type 2 diabetes: prospective observational study. Neth J Med. 2005;63:103–10. PubMed
Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009;52:789–97. CrossRefPubMed
Rutten GEHM, Verhoeven S, Heine RJ, de Grauw WJC, Cromme PVM, Reenders K. NHG-standaard Diabetes mellitus type 2 (eerste herziening). Huisarts Wet. 1999;42:67–84.
Cromme PVM, Mulder JD, Rutten GEHM, Zuidweg J, Thomas S. NHG-standaard Diabetes mellitus type II. Huisarts Wet. 1989;32:15–8.
Struck J. Diagnostic use of prosomatostatin. US patent WO2012167887 A1. http://www.google.com/patents/WO2012167887A1?hl=nl&cl=en. Accessed 22 february 2015
Riphagen IJ, Boertien WE, Alkhalaf A, Kleefstra N, Gansevoort RT, Groenier KH, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31). Diabetes Care. 2013;36:3201–7. CrossRefPubMedPubMedCentral
Díez-Marqués ML, García-Escribano C, Medina J, Boyano-Adanez MC, Arilla E, Torrecilla G, et al. Effects of somatostatin on cultured human mesangial cells. Endocrinology. 1995;136:3444–51. PubMed
Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int Suppl. 1997;60:S12–9. PubMed
- The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35)
Peter R van Dijk
Gijs WD Landman
Larissa van Essen
Klaas H Groenier
Henk JG Bilo
Stephan JL Bakker
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II